News & Information
May 8th Webcast: Biomarker Testing Needed Before Making Treatment DecisionsGuest Speaker: Dr. Todd D. Cohen, Medical Director at Myriad Genetics
Biomarker Testing Needed Before African American Patients Choose Active Surveillance
Thomas Farrington, PHEN President, outlines why genomic biomarker testing is needed by African American patients before they choose active surveillance....
Thomas Farrington, PHEN President, outlines why genomic biomarker testing is needed by African American patients before they choose active surveillance....
Innovative Format is Key to Reaching & Educating African Americans About Prostate Cancer
The “Daddy’s Boys” stage play, presented on tour by PHEN, draws 1,000+ national attendees per performance.
Prostate cancer diagnoses, deaths decreasing worldwide
Prostate caner, one of the deadliest forms of cancer for men in the United States and worldwide, is on the decline.
African American Men Respond Better to Treatments For Advanced Prostate Cancer in Clinical Trials
New research shows that African American men who receive treatments for late-stage prostate cancer can live at least as long, or even longer than their Caucasian counterparts.
Better Survival for African-Americans with Metastatic Prostate Cancer
African-American men with metastatic castration-resistant prostate cancer and no chemotherapy lived significantly longer than white men when treated with newer hormonal therapies.














Presenter: Todd D. Cohen, MD
VP of Medical Affairs
Medical Director of Urology
Myriad Genetics